Newsroom | 62378 results

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective August 5th, 2025, to three non-executive employees of non-qualified stock...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market,” said Masoud Toloue, CEO of Quanterix. “We have built a franchise that is gen...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the second quarter ended June 30, 2025. Recent Financial Highlights Generated total revenues of $546.6 million in the second quarter of 2025, compared to $413.4 million in the second quarter of 2024, an increase of 32.2%. Product revenues grew 32.3% over the same period. Generated a gross margin of 63.4% in the second quarter of 2025, com...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “The recent expansion of our T...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu...

TAMPERE, Finnland--(BUSINESS WIRE)--Im Rahmen von Forschungsarbeiten an historischer DNA, die das Museumszentrum Vapriikki in Tampere, Finnland, in Zusammenarbeit mit den Universitäten von Turku und Helsinki durchführte, konnten neue Erkenntnisse in Bezug auf Verwandtschaftsbeziehungen, Gesundheit und Fortbestand der Bevölkerung im Finnland des Mittelalters und der frühen Neuzeit gewonnen werden. Die in der Fachzeitschrift mit Peer-Review iScience veröffentlichten Forschungsergebnisse basieren...

TAMPERE, Finlandia--(BUSINESS WIRE)--Una ricerca sul DNA antico condotta dal Centro museale Vapriikki di Tampere, in Finlandia, in collaborazione con le università di Turku e Helsinki, ha fornito nuovi dati preziosi su parentela, salute e continuità della popolazione nella Finlandia medievale e della prima età moderna. I risultati della ricerca, pubblicati sulla rivista scientifica iScience dopo essere stati sottoposti a peer review, sono stati ottenuti dai resti di 25 persone in Finlandia – un...

TAMPERE, Finland--(BUSINESS WIRE)--Onderzoek naar oud DNA, geleid door het Museum Centre Vapriikki in Tampere, Finland, in samenwerking met de universiteiten van Turku en Helsinki, heeft nieuwe inzichten opgeleverd in verwantschap, gezondheid en bevolkingscontinuïteit in middeleeuws en vroegmodern Finland. Het onderzoek, gepubliceerd in het peer-reviewed tijdschrift iScience, presenteert de resultaten van 25 personen in Finland – een significant resultaat in een land waar zure bodems vaak leide...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is reaching additional global healthcare providers eager to use its PrecivityAD2™ blood test to help diagnose Alzheimer’s disease. The PrecivityAD2™ blood test allows healthcare providers to determine the presence or absence of amyloid pathology, a known hallmark of Alzheimer’s disease, for patients being evaluated for cognitive complaints through a simpl...